Holen Sie sich die Stockscreener-App
78.40
0.71%
-0.56
Schlusskurs vom Vortag:
$78.96
Offen:
$78.02
24-Stunden-Volumen:
259.51K
Relative Volume:
0.17
Marktkapitalisierung:
$10.53B
Einnahmen:
$3.10B
Nettoeinkommen (Verlust:
$586.71M
KGV:
18.26
EPS:
4.2937
Netto-Cashflow:
$605.57M
1W Leistung:
+2.74%
1M Leistung:
+5.53%
6M Leistung:
-16.44%
1J Leistung:
+24.98%
1-Tages-Spanne:
$78.00
$79.95
1-Wochen-Bereich:
$75.43
$79.95
52-Wochen-Spanne:
$59.51
$101.40
Globus Medical Inc Stock (GMED) Company Profile
Firmenname
Globus Medical Inc
Sektor
Branche
Telefon
610-930-1800
Adresse
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA
Compare GMED vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GMED
Globus Medical Inc
|
78.40 | 10.53B | 3.10B | 586.71M | 605.57M | 4.2937 |
ABT
Abbott Laboratories
|
98.23 | 169.98B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
93.29 | 119.33B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.60 | 113.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.12 | 63.94B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.58 | 50.48B | 6.30B | 1.07B | 1.09B | 1.8406 |
Globus Medical Inc Stock (GMED) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-28 | Eingeleitet | UBS | Neutral |
| 2026-07-09 | Eingeleitet | BMO Capital Markets | Outperform |
| 2026-01-30 | Hochstufung | Needham | Hold → Buy |
| 2026-01-27 | Eingeleitet | TD Cowen | Buy |
| 2025-11-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-11-07 | Hochstufung | Truist | Hold → Buy |
| 2025-10-28 | Fortgesetzt | Stifel | Hold |
| 2025-05-27 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-01-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-08-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-05-20 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-03-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-10-20 | Eingeleitet | ROTH MKM | Buy |
| 2023-09-19 | Hochstufung | Stifel | Hold → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-02-13 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-02-10 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-02-10 | Herabstufung | Loop Capital | Buy → Hold |
| 2023-02-10 | Herabstufung | Needham | Buy → Hold |
| 2023-02-10 | Herabstufung | Truist | Buy → Hold |
| 2023-02-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-04-13 | Fortgesetzt | Truist | Buy |
| 2022-03-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-01-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-12-13 | Hochstufung | BofA Securities | Underperform → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-29 | Eingeleitet | Loop Capital | Buy |
| 2021-02-18 | Fortgesetzt | Needham | Buy |
| 2020-12-08 | Eingeleitet | Citigroup | Buy |
| 2020-10-20 | Eingeleitet | Stifel | Hold |
| 2020-08-06 | Bestätigt | Needham | Buy |
| 2020-08-06 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-07-21 | Eingeleitet | Northland Capital | Market Perform |
| 2020-07-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-05-08 | Bestätigt | Needham | Buy |
| 2020-03-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2019-12-12 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-08-02 | Bestätigt | Needham | Buy |
| 2019-05-24 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-05-03 | Bestätigt | Needham | Buy |
| 2019-02-28 | Hochstufung | UBS | Neutral → Buy |
| 2019-01-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-06-27 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-06-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-05-03 | Bestätigt | Needham | Buy |
| 2018-04-04 | Hochstufung | Needham | Hold → Buy |
Alle ansehen
Globus Medical Inc Aktie (GMED) Neueste Nachrichten
Globus Medical Sets November 5 Earnings Report and Call - MyChesCo
Globus Medical, Inc. (GMED) Stock Forecasts - Yahoo! Finance Canada
GMED or AXGN: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Reasons to Add STE Stock to Your Portfolio Right Now - Zacks Investment Research
Haemonetics Gains 149.3% in a Year: What's Driving the Rally? - Zacks Investment Research
Is it Apt to Retain Medtronic Stock in Your Portfolio Now? - Zacks Investment Research
Is Spine Tech Unveiling Altering The Investment Case For Globus Medical Stock? - Yahoo Finance
RBC cuts target to USD 85.00 for Globus Medical stock - ad-hoc-news.de
BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients - Zacks Investment Research
Doximity Deepens U.S. News Alliance to Improve Patient Access to Care - Zacks Investment Research
Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now? - Zacks Investment Research
Is Globus Medical (GMED) Cheap On Its Spine Platform Reveal? - Yahoo Finance
What Does Globus Medical (GMED) Mean For Spine Care After Its NASS 2026 Reveal? - Yahoo Finance
Globus Medical (GMED) Stock Looks Discounted Against Its Earnings Outlook - Yahoo Finance
Globus Medical to Showcase SCRIPT™ Patient-Specific Implants and New XLIF™ Prone Procedural Solution at NASS 2026 - Orthopedics This Week
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? - Zacks Investment Research
Globus Medical, Inc. (GMED.MX) stock price, news, quote and history - Yahoo Finance UK
BTSG Stock Climbs 67.3% YTD: What's Driving the Rally in 2026? - Zacks Investment Research
Reasons to Add QuidelOrtho Stock to Your Portfolio for Now - Zacks Investment Research
Hims & Hers Expands Australian Women's Health Platform With Hers - Zacks Investment Research
A new platform is designed to let surgeons tailor spinal implants to each patient. Globus Medical will preview it at NASS. - Stock Titan
Globus Medical to Showcase SCRIPT™ Patient-Specific Implants and New XLIF™ Prone Procedural Solution at NASS 2026 - GlobeNewswire
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Zacks Investment Research
ISRG Is Expanding Beyond Surgery: Here's Why the GI Opportunity Matters - Zacks Investment Research
Here's Why You Should Add Avantor Stock to Your Portfolio for Now - Zacks Investment Research
Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms - Zacks Investment Research
Globus Medical to Announce Third Quarter 2026 Financial Results on November 5 and Hold Conference Call - Quiver Quantitative
Globus Medical Schedules Third Quarter Earnings Release and Conference Call - GlobeNewswire
Here's Why You Should Retain AMN Stock in Your Portfolio for Now - Zacks Investment Research
Globus Medical Q2 2026 Earnings Call Transcript - Benzinga
How Globus Medical Inc. Class A (GMED) Affects Rotational Strategy Timing - Stock Traders Daily
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y - Zacks Investment Research
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now - Zacks Investment Research
Is it the Right Time to Hold TNDM Stock in Your Portfolio? - Zacks Investment Research
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now - Zacks Investment Research
Globus Medical, Inc. (GMED) Stock Forecasts - Yahoo Finance
Globus Medical, Inc. (GMED) Stock forecasts - Yahoo Finance Singapore
RBC cuts target for Globus Medical stock to USD 85.00 - AD HOC NEWS
Is it the Right Time to Add Phibro Stock to Your Portfolio? - Zacks Investment Research
Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets - Zacks Investment Research
Reasons to Retain Hims & Hers Stock in Your Portfolio for Now - Zacks Investment Research
Should Globus Medical's Expanding Musculoskeletal Pipeline and Cash-Funded Growth Strategy Matter to GMED Investors? - Yahoo! Finance Canada
Should Globus Medical's Expanding Musculoskeletal Pipeline and Cash-Funded Growth Strategy Matter to GMED Investors? - Yahoo Finance
10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research - Zacks Investment Research
Here's Why You Should Retain WAT Stock in Your Portfolio for Now - Zacks Investment Research
Globus Medical (GMED) Stock Sees Modest Fair Value Cut As Analysts Split On Outlook - Yahoo Finance
Globus Medical, Inc. (GMED) Stock Forecasts - Yahoo Finance
Globus Medical stock faces a new Hold view at USD 73.90 - AD HOC NEWS
A Look at Globus Medical Inc (GMED) After 3.5% Decline -- GF Val - GuruFocus
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now - Zacks Investment Research
Finanzdaten der Globus Medical Inc-Aktie (GMED)
Umsatz
Nettogewinn
Free Cashflow
ENV
Globus Medical Inc-Aktie (GMED) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| TOBIN JAMES R | Director |
Sep 15 '26 |
Proposed Sale |
74.53 |
30,000 |
2,236,000 |
0 |
| TOBIN JAMES R | Director |
Sep 15 '26 |
Sale |
74.58 |
30,000 |
2,237,502 |
0 |
| ZARRILLI STEPHEN T | Director |
Aug 18 '26 |
Option Exercise |
53.27 |
25,000 |
1,331,750 |
25,000 |
| ZARRILLI STEPHEN T | Director |
Aug 18 '26 |
Sale |
87.04 |
25,000 |
2,175,965 |
0 |
| ZARRILLI STEPHEN T | Director |
Aug 18 '26 |
Proposed Sale |
87.04 |
25,000 |
2,176,000 |
0 |
| Davidar David D | Director |
Jun 05 '26 |
Proposed Sale |
81.00 |
25,000 |
2,025,000 |
0 |
| Davidar David D | Director |
Jun 05 '26 |
Option Exercise |
26.27 |
25,000 |
656,750 |
535,175 |
| Davidar David D | Director |
Jun 05 '26 |
Sale |
80.76 |
25,000 |
2,019,072 |
510,175 |
| RHOADS ANN D | Director |
Jun 04 '26 |
Option Exercise |
26.27 |
25,000 |
656,750 |
40,384 |
| DeFord John A | Former Director |
Apr 14 '26 |
Proposed Sale |
93.10 |
30,000 |
2,793,128 |
0 |
1.62%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):